Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-5948 in adult patients with relapsed/refractory (R/R) B cell malignancies who have received at least 2 prior lines of therapy and for whom no other therapies are known to provide clinical benefit. Indications include: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), non-germinal center B-cell subtype (non-GCB) Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) including those with secondary CNS involvement in any disease indication listed, or Primary Central Nervous System Lymphoma (PCNSL).~Phase 1b will investigate the efficacy of NX-5948 at the dose(s) selected in Phase 1a in up to 4 cohorts of patients with histologically confirmed R/R B-cell malignancy indications who have received at least 2 prior lines of therapy (or at least 1 prior line for patients with WM or PCNSL):~CLL or SLL including those with secondary CNS involvement of their disease~Non-GCB DLBCL or MCL including those with secondary CNS involvement of their disease~MZL, WM, or FL including those with secondary CNS involvement of their disease~PCNSL
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.